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MIF is a chemokine-like cytokine that plays a role in the pathogenesis of inflammatory and 
cardiovascular disorders. It binds to the chemokine-receptors CXCR2/CXCR4 to trigger atherogenic 
leukocyte migration albeit lacking canonical chemokine structures. We recently characterized an N-like-
loop and the Pro-2-residue of MIF as critical molecular determinants of the CXCR4/MIF binding-site and 
identified allosteric agonism as a mechanism that distinguishes CXCR4-binding to MIF from that to the 
cognate ligand CXCL12. By using peptide spot-array technology, site-directed mutagenesis, structure-
activity-relationships, and molecular docking, we identified the Arg-Leu-Arg (RLR) sequence-region 
87–89 that – in three-dimensional space – ‘extends’ the N-like-loop to control site-1-binding to CXCR4. 
Contrary to wildtype MIF, mutant R87A-L88A-R89A-MIF fails to bind to the N-terminal of CXCR4 and 
the contribution of RLR to the MIF/CXCR4-interaction is underpinned by an ablation of MIF/CXCR4-
specific signaling and reduction in CXCR4-dependent chemotactic leukocyte migration of the RLR-
mutant of MIF. Alanine-scanning, functional competition by RLR-containing peptides, and molecular 
docking indicate that the RLR residues directly participate in contacts between MIF and CXCR4 and 
highlight the importance of charge-interactions at this interface. Identification of the RLR region adds 
important structural information to the MIF/CXCR4 binding-site that distinguishes this interface from 
CXCR4/CXCL12 and will help to design MIF-specific drug-targeting approaches.
Chemokines (CKs) are a complex family of 49 small chemotactic polypeptides, which along with their 23 recep-
tors orchestrate leukocyte migration processes in health and disease. They are structurally characterized by con-
served N-terminal cysteine residues and a so-called chemokine-fold and they are sub-divided into four main 
classes, the CC-, CXC-, C-, and CXXXC-chemokines, based on the nature of the cysteine motif. Chemokine 
receptors (CKRs) are typical G protein-coupled receptors (GPCRs) with seven transmembrane-spanning 
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α-helices and a C-terminal heterotrimeric G protein-binding domain. CKRs are grouped according to the 
class of chemokine ligand(s) they interact with. In addition, atypical CKRs (ACKRs) that do not support Gi 
protein-mediated signaling have been defined. Owing to the GPCR nature of chemokine receptors and the 
involvement of chemokines in numerous pathophysiologic processes they are attractive drug targets1–4.
Recent advances in GPCR crystallography have led to the elucidation of the three-dimensional structures 
of the chemokine receptor CXCR4 complexed to small molecule ligands and the herpesvirus-8 chemokine 
vMIP-II5,6, CCR5 with the FDA-approved compound maraviroc7 and a chemokine8, CX3CL1 in complex with 
the human cytomegalovirus GPCR US289, CCR2 in complex with orthosteric and allosteric antagonists10, and 
an intracellular antagonist with CCR911. The structure of CXCR1 has been solved by NMR spectroscopy12. 
Together with structure-activity relationship (SAR) experiments, these studies have helped to understand the 
activation of chemokine receptors by their cognate ligands and the elicited cellular signaling processes. Most CKs 
have a two-site mechanism for binding their receptors13,14. Site 1 involves interactions between the chemokine 
N-loop, which follows the N-terminal cysteine motif, and the receptor N-domain. The interactions for site 2 
are between the chemokine N-terminal residues prior to the cysteine motif and the extracellular loops (ECLs), 
e.g. the Glu-Leu-Arg sequence for ELR + chemokines such as CXCL8 in its engagement of CXCR1 or CXCR213. 
Furthermore, chemokine responses may be fine-tuned by interactions with neighboring glycosaminoglycans 
(GAGs)15,16. Agonist interactions for the homeostatic chemokine receptor CXCR4 are less well understood despite 
the available X-ray crystallographic information5,6. For CXCR4 and its cognate ligand CXCL12 (also known as 
SDF-1α), the CXCL12 N-loop is comprised of a RFFESH sequence, which interacts with the CXCR4 N-domain 
(site 1)17. CXCL12 lacks an ELR motif and its disordered N-terminus interacts with ECL2 of CXCR4 and pene-
trates into the transmembrane cavity of the receptor (site 2)5,13,17.
Macrophage migration inhibitory factor (MIF) is a multi-functional chemokine-like cytokine that plays a 
pivotal role in the pathogenesis of numerous inflammatory and cardiovascular disorders such as sepsis, rheu-
matoid arthritis, systemic lupus erythematosus, inflammatory lung diseases, myocardial ischemia/reperfusion 
injury, and atherosclerosis18–22. It is the prototypical member of an emerging family of mediators with both intra- 
and extracellular activities termed atypical chemokines (ACKs) or chemokine-like function (CLF) chemokines 
that, once secreted into the extracellular space, bind to and activate classical chemokine receptors albeit lacking 
the canonical structural elements23–25. Other examples of ACKs are human β-defensin-1 (HBD-1) that binds to 
CCR6, a secreted tyrosyl tRNA synthetase fragment that is an agonist of CXCR1, or β3-defensin that is an ago-
nist for CXCR4. A complex between the alarmin HMGB1 and CXCL12 also binds to CXCR424,26. Thus, ACKs 
add significantly to the complexity and redundancy within the CK/CKR network, but also serve to fine-tune 
the signaling responses and to increase variability in the network. Like their classical chemokine counterparts, 
ACKs have been recognized as important players in inflammatory and cardiovascular disease25,27–29. ACKs are 
a heterogeneous functional family of proteins and most members do not share structural similarity with each 
other24,25. Accordingly, the structural basis underlying the engagement of chemokine receptors by these mediators 
is relatively poorly understood and is likely to differ for each member or chemokine-like function. One example 
of an ACK for which structural information regarding its binding interface with a cognate CKR has been obtained 
is HBD1, which mimics a charge cluster exposed on the outside of the three-dimensional structure of CCL20/
MIP-3α, the cognate ligand of CCR627, but mimicry elements will be different for other ACKs.
MIF exerts its chemokine activities through interactions with the CXC chemokine receptors CXCR2 
and CXCR4 to elicit atherogenic leukocyte recruitment. It also binds to the type-II receptor CD74/invariant 
chain, driving cell-proliferative responses in inflammation and cancer, and to the chemokine scavenger recep-
tor CXCR7/ACKR324,25,30–32. We showed that MIF binds to CXCR2 by a two-site binding mechanism involv-
ing an N-like loop and a pseudo-ELR motif within MIF, thus mimicking interactions between CXCR2 and its 
ELR + ligand CXCL830,33,34. In contrast, the interaction between MIF and CXCR4 remains incompletely under-
stood. We recently characterized an extended N-like loop and the evolutionarily conserved Pro-2 residue of MIF 
to constitute critical molecular determinants of the CXCR4/MIF binding site and identified partial allosteric 
agonism as the mechanism that distinguishes CXCR4 binding to MIF from that to the cognate ligand CXCL1235. 
Yet, due to the lack of a RFFESH motif in MIF and its conformationally constrained N-terminus36, this only partly 
explains the affinity and specificity observed for the MIF/CXCR4 interaction24,25,30.
Here, we applied peptide spot array technology, site-directed mutagenesis, structure-activity relationship 
studies, and molecular docking to identify a discontinuous three-amino acid stretch (Arg-Leu-Arg; RLR) that 
is remotely located at the C-terminal end of the second α-helix in MIF which may serve to extend the N-like 
loop of MIF and contribute to site 1 binding to CXCR4. The contribution of these residues to functional MIF/
CXCR4 interactions was tested using a CXCR4-specific yeast-based cellular signaling system37 and a MIF/
CXCR4-dependent chemotactic leukocyte migration assay. We also performed alanine scanning and molecular 
docking techniques to understand the structural details as well as investigate if the RLR motif directly takes part 
in site 1 contacts between MIF and CXCR4.
Results
Identification of the RLR residues, expression and biochemical characterization of the MIF 
R87A-L88A-R89A triple mutant. We previously showed that an extended N-like loop sequence in MIF 
contributes to site 1 binding with CXCR435. The N-like loop comprises a flexible loop region followed by residues 
of the ensuing β-strand. Residues at the C-terminal of this region have been implied in binding to MIF receptor 
CD74 (amino acids 79–86)38, but not in interactions between MIF and CXCR4.
Peptide spot array analysis of the C-terminal region of the extended N-like loop of MIF using immobilized 
15-mer human MIF peptides with each peptide positionally shifted by three residues, was probed for binding 
to biotinylated CXCR4 N-terminus (CXCR4(1–27)). Analysis revealed a marked signal for MIF peptides 82–96 
and 85–99, while giving a small signal for peptide 79–93 and no signal for peptides 88–102 and 91–105 (Fig. 1a). 
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Among the residues shared by the responsive peptides was the Arg-87-Leu-88-Arg-89 (RLR) sequence seg-
ment. Considering sequences comprising basic residues such as Arg or Lys have been found to contribute to 
the site 1 interaction surface between CXCL12 and CXCR439, we hypothesized the RLR region may contribute 
to MIF/CXCR4 binding. To further test the potential relevance of this sequence, the influence of N-terminal 
or C-terminal neighboring amino acids, and peptide length, we also analyzed peptides 71–90, 73–90, 74–89, 
75–90, 76–90. Peptide 76–86 was used as an RLR-void control. Overall, this analysis confirmed a role for the RLR 
sequence of MIF in CXCR4(1–27) binding. While the comparison of the tested peptides in Fig. 1a also implied 
that a net positive charge (+1 versus 0 or −1) may foster the interaction with CXCR4(1–27), the extended com-
parison of probed peptides in Fig. 1b suggested that signal strength also is modulated by N-terminal extension 
of the RLR sequence, while N-terminally extended peptides with a net positive charge of +2 showed higher 
signal intensities than the shorter peptides with a net charge of +3 (Fig. 1b). A more specific role for the RLR 
sequence also was confirmed by a control experiment using randomized - ‘scrambled’ – peptides. Binding of 
biotin-CXCR4(1–27) to peptide 75–90, i.e. the strongest interacting MIF peptide tested, was compared with the 
binding of five randomized - ‘scrambled’ – sequences of MIF peptide 75–90. Supplementary Fig. 1 shows that 
binding of the scrambled peptides to CXCR4(1–27) was markedly lower than binding of the RLR-containing 
wildtype sequence.
When we inspected the position of RLR in the three-dimensional structure of MIF, it appeared that residues 
87–89 are positioned in the vicinity of the N-like loop of MIF. RLR is located at the C-terminal end of the second 
α-helix, with the two arginine residues of RLR being surface-exposed and the leucine making hydrophobic con-
tacts (see ref.)36. Overall, this may lead to an expansion of the surface of the N-like loop, both in the monomeric 
and trimeric structures of MIF (Fig. 1c). Interestingly, CXCR4(1–27) comprises seven negatively charged residues 
(Glu-2, Asp-10, Glu-14, Glu-15, Asp-20, Asp-22, Glu-26) that could qualify for interactions with the positive 
Figure 1. Identification of the RLR sequence as a potential MIF binding region to the N-terminal peptide 
of CXCR4. (a,b) The peptide spot microarray method suggests that the RLR tripeptide at sequence position 
87–89 may contribute to MIF/CXCR4 binding. A peptide spot array containing 15-mer spotted MIF peptides 
positionally shifted by three amino acids were probed with biotin-CXCR4(1–27). Graphs are plots of spotted 
MIF peptides over the intensity of the binding signal to biotin-CXCR4(1–27) as read-out by streptavidin Cy5.5 
fluorescence. (a) Of five positionally shifted 15-mer peptides of the region 79–105 only peptides containing 
RLR interact with CXCR4(1–27). (b) Binding of RLR-containing MIF peptides is modulated by N-terminal 
extension, but residues N-terminal of RLR do not exhibit binding activity per se. (c) Structural model of MIF 
(as monomer and trimer) and position of the N-like loop (green) and the RLR sequence (red). Note: in the 
three-dimensional conformation of the monomer, RLR is located in the vicinity of the N-like loop of MIF. The 
trimeric structure shows that both the N-like loop and RLR are surface-exposed on the trimer (see also Fig. 7).
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charges within RLR of MIF. Therefore based on these initial data, we hypothesized that the RLR sequence stretch 
could contribute to the site 1 binding region between MIF and its chemokine receptor CXCR4.
A triple alanine mutant of MIF (R87A-L88A-R89A-MIF) was expressed in E. coli BL21/DE3. The expres-
sion efficiency of the mutant was lower than that of WT-MIF. The mutant was recovered from the cleared bac-
terial lysate and did not form inclusion bodies. It has a predicted lower isoelectric point than WT-MIF (pI 
(R87A-L88A-R89A-MIF) = 6.1) compared to 7.73 for WT-MIF and a predicted higher grand average of hydrop-
athy (GRAVY) (0.090434 versus −0.001739; Supplementary Fig. 2). Accordingly, we chose a purification strategy 
that was different from that established for WT-MIF40. Whereas WT-MIF does not bind to an anion exchange 
column at pH 7.540, R87A-L88A-R89A-MIF interacts with the anion exchange material under these conditions. 
The mutant protein was eluted from the anion exchange column via salt gradient and subjected to size exclusion 
chromatography (SEC) for further purification. The RLR mutant eluted at peaks with an approximate molecular 
size of 23 and 38 kDa, suggesting that it forms dimers and trimers under these conditions (Supplementary Fig. 3). 
Similar to WT-MIF41,42, these oligomers constituted the major peak(s) in the size exclusion chromatogram, but 
the mutant additionally also showed several high molecular weight peaks (52–124 kDa), likely representing high 
molecular weight oligomers or aggregates. Applying this procedure, the mutant protein was obtained in appreci-
able yield, purity, and free of endotoxin contamination, as confirmed by SDS-PAGE silver-staining and Western 
blot analysis of the obtained fractions (Fig. 2a,b and Supplementary Table 1).
Figure 2. Expression, purification, and conformational integrity of R87A-L88A-R89A-MIF. (a) Recombinant 
expression and purification of R87A-L88A-R89A-MIF by anion exchange chromatography (Q Seph) and 
size exclusion chromatography (SEC, gel filtration) as analyzed by SDS-PAGE and silver staining. Total 
lysate, bacterial lysate after IPTG induction; Q Seph - elution, specific elution of protein from Q sepharose 
column by increasing salt gradient; Q Seph – FT, flow-through; gel filtration F1-F5, elution fractions 1–5 (see 
Supplementary Fig. 3). (b) Same as (a) but analysis by Western blot using a polyclonal anti-MIF antibody. (c) 
Circular dichroism (CD) spectropolarimetry shows that the folding and secondary structure profile of R87A-
L88A-R89A-MIF is overall similar to that of WT-MIF. Spectra of R87A-L88A-R89A-MIF and WT-MIF at 
different concentrations are presented according to the indicated color code. Conformations in the CD spectra 
were measured as mean residue ellipticity versus the wavelength in the far-UV range.
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Next, we performed circular dichroism (CD) spectropolarimetry to address the question whether the alanine 
substitutions at the RLR site affect the structural integrity of MIF. Far-ultraviolet (UV) spectra were recorded 
between 195 and 250 nm and the spectrum of the RLR mutant compared with that of WT-MIF. CD spectroscopy 
provides a good estimation of the secondary structural profile of a protein and records relative changes in average 
secondary structural content, e.g. when a mutated protein is compared to its wildtype counterpart. Figure 2c 
shows that the secondary structure profile of the RLR mutant is similar to that of WT-MIF. Significant changes 
were limited to the spectral region below 210 nm. Dose-dependent recordings at 1, 2.5, and 5 µM did not lead to 
substantial spectral changes, neither for WT-MIF nor for the triple alanine mutant, indicating that neither pro-
tein showed an aggregation-tendency in this concentration range. Moreover, the quantification of the secondary 
structural contents following deconvolution of the CD spectra applying Dichroweb43,44 indicated that approxi-
mately 80% of the average ordered secondary structural content remained unaffected by the alanine substitutions 
(Supplementary Table 2). The deconvolution of the CD spectra also indicated that the typical α/β-structure of 
WT-MIF36,40 was preserved in the mutant, although the α-helix content, and to a lower extent, the β-strand per-
centage, in the mutant protein were found to be reduced by 12% and 7%, respectively, compared to the WT-MIF 
protein (Supplementary Table 2). In turn, random coil content was increased in the mutant by approximately 
20%. Overall, the biochemical and biophysical data indicated that the alanine substitutions did not substantively 
interfere with the overall structural integrity of the MIF protein, although smaller changes of the average second-
ary structural content were observed and slight alterations on tertiary structure level cannot be excluded.
The RLR residues contribute to MIF/CXCR4 binding and the CXCR4-mediated cellular signaling 
activity of MIF. We previously determined the binding interaction between Alexa-488-labeled WT-MIF 
and CXCR4(1–27) by fluorescence spectroscopic titration. The Kd was estimated to be in the range of 10 µM35. 
Here, we performed fluorescence titrations with different concentrations of CXCR4(1–27) and Alexa-488-labeled 
R87A-L88A-R89A-MIF. The fluorescence emission of Alexa-488-labeled R87A-L88A-R89A-MIF at 522 nm did 
not exhibit any dose-dependent changes up to a 763-fold molar excess of CXCR4(1–27) (Supplementary Fig. 4). 
This suggested that R87A-L88A-R89A-MIF does not bind to CXCR(1–27) and supports the notion that the RLR 
peptide contributes to MIF/CXCR4 binding.
To address the contribution of the RLR motif to MIF/CXCR4-specific cell signaling responses, we employed 
a genetically modified strain of Saccharomyces cerevisiae that replaces the yeast ste2 GPCR with human CXCR4 
as previously reported35. This cell system eliminates complications from mammalian cells that usually express 
more than one or all MIF cell surface receptors and is based on agonist-mediated activation of CXCR4 lead-
ing to a signaling cascade that results in β-galactosidase expression from the Fus1-lacZ reporter plasmid. We 
recently demonstrated that MIF activates CXCR4 signaling in this system. MIF agonism is similar but not identi-
cal to that of CXC12, exhibiting partial allosteric agonism in comparison with CXCL1235. Recombinant WT-MIF 
but not a control buffer triggered a marked CXCR4 response as previously reported35 (Fig. 3a). In contrast, 
R87A-L88A-R89A-MIF failed to activate CXCR4 (Fig. 3a), confirming that the RLR sequence is involved in MIF/
CXCR4 binding, and suggesting that it is necessary for MIF/CXCR4-mediated cell signaling.
Although the yeast cell system elegantly bypasses the problem of multiple MIF receptor expression in mam-
malian cells, it is somewhat artificial in that yeast features an outer cell wall in addition to the plasma mem-
brane, necessitating the use of micromolar concentrations of agonists due to impaired access to CXCR4 in the 
membrane35,45. We thus next wished to confirm and extend these findings in a cell system with an even higher 
physiological and pathophysiological relevance. One major function of the MIF/CXCR4 axis is to support the 
chemotactic recruitment of T and B lymphocytes30,32,46,47. Here, we employed the human B cell line JVM-3, which 
expresses significant levels of the MIF receptors CXCR4 (Supplementary Fig. 5) and CD74, but not CXCR2 or 
CXCR7 (T. Thavayogarajah, D. Sinitski, and J. Bernhagen, unpublished observation) and is an established cell 
model to monitor chemokine-mediated chemotactic migration responses48. Figure 3b demonstrates that CXCL12 
elicited a marked JVM-3 chemotaxis response (CTXCXCL12 = 3.5 ± 0.4, p < 0.0001). The chemotactic effect of 
WT-MIF was lower than that of CXCL12 as previously seen, followed a concentration-dependence, and was sim-
ilar to previously observed chemotactic effects of MIF on mouse B cells46 (8 nM: CTXMIF = 1.58 ± 0.4, p = 0.07; 
16 nM: CTXMIF = 2.43 ± 0.06, p < 0.0001). The RLR mutant did not exhibit a significant chemotactic activity on 
JVM-3 B cells at any of the concentrations tested (8 nM, 16 nM, 32 nM; p = ns; Fig. 3b). This suggested that the 
RLR sequence segment significantly contributes to MIF/CXCR4-mediated chemotactic cell migration responses.
Direct involvement of the RLR sequence in MIF/CXCR4 interactions. To obtain evidence that the 
RLR residues are directly involved in the MIF/CXCR4 interface, we combined the peptide spot array technology 
of the C-terminal region of the extended N-like loop of MIF with an alanine scanning approach. 15-mer human 
MIF peptides 75–89, 78–92, and 84–98, containing RLR in the C-terminal, middle or N-terminal part of the 
sequence, respectively, were synthesized as either wildtype sequence or as one of nine different alanine scan var-
iants, with one or two alanine substitutions introduced across the entire sequence length (Fig. 4). Immobilized 
alanine scan variants were then probed for binding to biotinylated CXCR4(1–27). As expected from the peptide 
array analysis of RLR-containing MIF 15-mer peptides (Fig. 1), wild-type peptides 75–89, 78–92, and 84–98 
bound CXCR4(1–27) with signal intensities between 2000 and 4000 LU. Overall, alanine scanning supported the 
notion that only alanine substitutions of the RLR region itself led to marked reductions in CXCR4(1–27) binding 
activity (Fig. 4a–c). This is most apparent in peptides 75–89 and 78–92. An exception is the alanine substitution of 
residues 94 and 95 in peptide 84–98. Interestingly, residue 94 in WT-MIF is an arginine, insinuating that another 
positively charged amino acid in the vicinity of RLR may further contribute to MIF/CXCR4 binding. One other 
intriguing observation was made in the alanine scanning experiment. The substitution of the glutamic acid (res-
idue 86) immediately preceding RLR in peptides 75–89 and 84–98 led to a pronounced increase in the binding 
signal (Fig. 4a,c). The substitution of glutamic acid by alanine at this position eliminates a negative charge in the 
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vicinity of RLR, supporting the conclusion that a net positive charge within RLR or in its immediate vicinity is 
important for CXCR4(1–27) binding. Altogether, these data show that only alanine substitutions within or in the 
vicinity of RLR lead to alterations in CXCR4(1–27) binding activity, suggesting a direct role for this MIF region 
in the MIF/CXCR4 binding interface.
To confirm this notion, we asked whether the RLR-spanning peptides MIF(86–100 or ERLRISPDRVYINYY) 
and MIF(76–90 or YSKLLCGLLAERLRI), i.e. peptide sequences with strong binding signals in the peptide array 
experiments and a representing more N-terminal and C-terminal RLR positions, respectively, are able to interfere 
with MIF-mediated JVM3 B cell chemotaxis. The competition experiments adding different concentrations of the 
RLR-spanning peptides together with 16 nM of full-length WT-MIF into the chemotaxis chambers showed that 
both peptides competed with WT-MIF, leading to a reduction/ablation of the CXCR4-dependent chemotactic 
activity of MIF (Fig. 5). Peptide MIF(86–100) showed a concentration-dependent competition behavior with a 
trend towards inhibition seen at concentrations of 10 and 100 nM, and a significant and complete blockade of MIF 
activity at a concentration of 1 µM. Peptide MIF(76–90) was even more potent and ablated the CXCR4-dependent 
chemotactic activity of MIF at concentrations of 10 and 100 nM. Together, the peptide competition experiment 
corroborated the notion that the RLR region directly contributes to functional MIF/CXCR4 interactions.
Finally, we tested this structural concept by molecular docking simulations. The N-terminal 22 or 26 amino 
acids of CXCR4, respectively, did not have interpretable density in the available CXCR4 X-ray structures5,6. 
However, a recent nuclear magnetic resonance (NMR)-based structure of the complex between CXCR4(1–38) 
Figure 3. Mutation of the RLR residues markedly impairs CXCR4-dependent MIF cell signaling activities. (a) 
MIF signaling through CXCR4 in S. cerevisiae is abolished in R87A-L88A-R89A-MIF. CXCR4 replaces the Ste 
2 receptor pheromone response pathway of S. cerevisiae. The pathway is further modified to enable activated 
human CXCR4 to elicit a robust signaling response that couples to the expression of different levels of lacZ gene 
dependent on the level of signaling, which is measured by enzymatic activity. Enzymatic activity is represented 
as relative luminescence. The concentrations of WT-MIF and RLR mutant are as indicated. Corresponding 
control buffers were used for WT-MIF (control 1) and the RLR mutant (control 2). Values are means ± SD 
of 3–9 replicates representing three-to-four experiments. (b) Impaired chemotactic effect of R87A-L88A-
R89A-MIF in CXCR4-dependent lymphocyte migration. Chemotactic migration (represented as chemotactic 
index) of JVM-3 lymphocytes towards R87A-L88A-R89A-MIF is compared with that elicited by WT-MIF at 
the indicated concentrations and CXCL12 (8 nM). PBS buffer was used as negative control to normalize for 
spontaneous random migration (control). The bar graph shows means ± SD of 3–5 experiments. **p < 0.01; 
***p < 0.005; ****p < 0.001.
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and a CXCL12 monomer provides structural information about the amino terminus of human CXCR449. We 
subjected this structure of the CXCR4 N-terminus (2n55 CXCR4 Nterm.pdb) and the structure of human MIF 
(hMIF 3djhmonomer.pdb) to the PATCHDOCK molecular docking algorithm that is based on shape comple-
mentarity principles. Both the restricted analysis, confined to residues 1–27 of the N-terminus, and the unre-
stricted approach, covering all 38 amino acids of the N-terminus, provided similar results in the PATCHDOCK 
calculation (data not shown) and were submitted to FIREDOCK for refinement and rescoring. For the highest 
ranked docking solution, a global energy of −43.76 kcal/mole was obtained for the MIF/CXCR4(1–38) complex. 
The following 10 lower ranked solutions also had global energies >30 kcal/mole. Similar results were obtained for 
the complex with CXCR4(1–27). Figure 6 illustrates the structures obtained for the highest ranked docking solu-
tion of the complex between human MIF and the CXCR4 N-terminal. The molecular docking result confirms the 
notion that the N-terminus of CXCR4 could engage in multiple direct interactions with both the N-like loop and 
the RLR tripeptide area (Fig. 6a–c). Moreover, GPCRs are known to be dynamic and the N-terminal of CXCR4 is 
conformationally flexible5,6,49, facilitating dynamic ligand contacts. A potential charge interaction between Arg-89 
of the MIF RLR sequence and Asp-20 of the CXCR4 N-terminal is indicated (Fig. 6d).
Overall, these data suggest that the RLR region directly contributes to the MIF/CXCR4 binding interface to 
control CXCR4-mediated cellular effects of MIF. Charge interactions could play an important role in stabiliz-
ing the binding interface. In fact, the interaction between CXCR4 and its known ligands CXCL12 and human 
β-defensin-3 (HBD3) involves charge clusters39,50. We have compared the sequence and structure of MIF with 
that of the CXCR4 ligands CXCL12 and HDB3 and analyzed the positions of residues, motifs, and charge clusters 
that have been implicated in the interaction with CXCR4 (Figs 7 and 8, and Supplementary Fig. 6). Figure 7a and 
Supplementary Fig. 6 highlight the residues and motifs in MIF that have previously been implicated in site 1 and 
2 interactions between MIF and CXCR4 and compare them to the presumed corresponding residues in CXCL12 
and HBD3. Of note, the MIF RLR sequence could represent a positive charge cluster similar to those represented 
by the K1-R8-R12 residues or the KHLK motif in CXCL12 as well as the K8-K32-R36 cluster in HBD3 (Fig. 7)39,50. 
This notion is supported when comparing the surface charges in these regions between MIF, CXCL12, and HBD3 
(Fig. 8).
Figure 4. Alanine scanning of RLR-containing MIF peptides reveals role for RLR in binding the CXCR4 
N-terminal peptide 1–27. A peptide spot array containing spotted 15-mer MIF peptides (a) 75–89, (b) 78–92, 
and (c) 84–98 was subjected to alanine scanning and probed with biotin-CXCR4(1–27). Sequential mono- or 
di-alanine substitutions were performed across the entire sequence of the peptides as indicated. Graphs are plots 
of spotted MIF/Ala scan peptides over the intensity of the binding signal to biotin-CXCR4(1–27) as read-out by 
streptavidin Cy5.5 fluorescence. Bars for wild-type peptides without alanine substitution are depicted in black; 
the position of the RLR sequence is framed.
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Discussion
MIF is a pivotal inflammatory cytokine18,20,25 and prototypical atypical chemokine (ACK) that exhibits key ACK 
features24,25,30. This study identifies residues in MIF, namely the Arg-Leu-Arg (RLR) tripeptide region, that con-
tribute to site 1 binding of the MIF/CXCR4 interface to control CXCR4-mediated cellular effects of MIF. With an 
N-like loop and the Pro-2 residue previously identified to support MIF/CXCR4 binding35, the current study com-
pletes the picture as to how an ACK such as MIF engages a classical chemokine receptor (CKR) such as CXCR4 
and will help to mechanistically understand differences versus similarities between MIF-mediated CXCR4 sign-
aling and that of the cognate ligand.
Chemokine receptors control numerous cellular pathways and orchestrate leukocyte trafficking under physio-
logical and pathophysiological conditions. Hence, CKs and their receptors have been implicated as pivotal medi-
ators in numerous diseases, e.g. inflammatory and cardiovascular diseases, autoimmune conditions, or cancer. As 
prototypical GPCRs of the Gαi subtype, CKRs are druggable and numerous small molecule and peptide-based 
inhibitors are being pursued as potential therapeutic candidates, but considerable challenges remain51,52. In par-
ticular, it has been difficult to devise CKR-specific approaches. The specificity problem occurs partly because the 
same receptor is expressed by different cell types but is activated by different chemokines expressed in various 
tissues and can potentially lead to adverse effects4. Accordingly, chemokine signaling mechanisms underlying 
ligand, receptor, and tissue bias are extensively studied.
The ACK activities of MIF contribute to its key role in inflammatory and cardiovascular diseases and cancer. 
For example, the MIF/CXCR2 axis controls atherogenic monocyte recruitment30 and natural killer T (NKT) cell 
migration in inflammatory skin conditions53. CXCR4-mediated MIF cell signaling activities encompass ather-
ogenic lymphocyte recruitment30,32,46, ischemia-triggered endothelial progenitor cell migration54,55, eosinophil 
inflammation56, promotion of inflammatory platelet survival57, or colon cancer cell metastasis58. It would thus be 
desirable to therapeutically interfere with these pathophysiological activities. However, there are multiple home-
ostatic and ‘beneficial’ functions mediated by CXCR4 following activation with its bona fide ligand CXCL12 such 
as cell homing, cardiac development, or neutrophil egress24,59,60. Also, CXCR4 can form receptor complexes with 
CD7430,61, and MIF/CD74 signaling has important cardioprotective activities in myocardial ischemia/reperfusion 
injury62,63. In atherosclerosis, recent cell-specific knockouts of CXCR4 as well as the study of neutrophil-mediated 
atherogenic effects has established that the CXCR4/CXCL12 axis has cell-dependent protective or exacerbating 
effects64–66.
Thus, to interfere with disease-promoting activities of the MIF/CXCR4 axis, specifically tailored targeting 
strategies need to be established that block MIF- but not CXCL12-mediated CXCR4 functions. This in turn 
requires a detailed structural understanding of the MIF/CXCR4 binding interface. We recently demonstrated that 
the unique N-terminal Pro-2 residue of MIF and its N-like loop region that MIF shares with classical chemokines 
are important determinants of the MIF/CXCR4 interface and that MIF activates CXCR4 by partial allosteric 
agonism compared with CXCL1235. However, these structural features can only partially explain the high binding 
affinity between MIF and CXCR4, and the various functional differences to CXCL12/CXCR424,30. Although the 
reactivity of Pro-2 is unique and the cavity that contains it is an excellent druggable site67, Pro-2 is involved in 
Figure 5. RLR-containing 15-mer MIF peptides block MIF/CXCR4-dependent JVM-3 lymphocyte 
chemotaxis. Chemotactic migration (represented as chemotactic index) of JVM-3 lymphocytes towards WT-
MIF (16 nM) in the presence versus absence of different concentrations of RLR-containing peptides MIF(76–
90) or YSKLLCGLLAERLRI and MIF(86–100) or ERLRISPDRVYINYY as indicated. PBS buffer was used as 
negative control to normalize for spontaneous random migration (control). The bar graph shows means ± SD 
of 3–12 replicates and represent 2–3 experiments. Statistical comparisons were done between the MIF and 
MIF + peptide data sets (*p < 0.05; ***p < 0.005) and between control and MIF (§§§p < 0.005).
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MIF/CD74 binding as mutations of Pro-2 impair MIF signaling responses68. Inhibition at this site could be prob-
lematic in cardiovascular diseases, as MIF/CD74 signaling conveys cardioprotection in early ischemia/reperfu-
sion injury in the heart via activation of the tissue-protective AMP kinase pathway62,63. MIF-targeting strategies 
should therefore ideally obviate Pro-2 and nearby residues as well as MIF region 79–85, both of which have been 
implicated in mediating CD74 activation38,68.
In the current study, we have addressed these requirements by further characterizing the MIF/CXCR4 inter-
face. We have identified an important additional structural element that contributes to the MIF/CXCR4 inter-
face and is required for critical CXCR4-mediated MIF functions. Using biochemical/biophysical techniques and 
structure-activity studies in conjunction with peptide array technology, CXCR4-controlled cell function analysis, 
alanine scanning, and molecular docking, we show that an RLR tripeptide located at position 87–89 of the MIF 
sequence is positioned in close proximity to the N-like loop of MIF, contributes to the MIF/CXCR4 binding inter-
face, and is functionally involved in CXCR4-mediated MIF activities. The peptide array and docking experiments 
suggest an important role for charge interactions by RLR arginine residues, in line with the view that electro-
static interactions are important in protein-protein interactions in general and in CXCR4/ligand interactions in 
particular.
Initial evidence for a role of RLR was obtained by a peptide spot array experiment, when we tested the binding 
of numerous RLR-spanning 15-mer peptides to the N-terminal sequence of CXCR4 using biotin-CXCR4(1–27). 
Although the N-terminal sequence of CXCR4 is not ‘visible’ in the available X-ray crystallographic structures 
of CXCR4, it has also been implicated in interactions with the cognate ligand CXCL12 by structure-activity 
studies and a recent NMR spectroscopy structure of a complex between CXCL12 and the N-terminal peptide 
1–38 of CXCR4 together with NMR/X-ray structure hybrid modeling suggested a distinct role for the receptor 
N-terminus in chemokine recognition and receptor activation5,6,49. Of note, the N-terminal region of CXCR4 had 
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Figure 6. Structure model of the complex between human MIF and the N-terminus of CXCR4 as determined 
by molecular docking. Ribbon structures of the complex between full-length human MIF and human 
CXCR4(1–38) as determined by molecular docking are shown in different orientations with and without the 
representation of side chains. (a) Ribbon structure of the complex between MIF and CXCR4(1–38) without 
depicting any side chains. The following color code was used: MIF structure (green), CXCR4 N-terminus (red), 
RLR sequence of MIF (magenta), N-like loop of MIF (blue), residues 28–38 of CXCR4 (turquoise). (b) Same 
as (a) in slightly rotated orientation with relevant side chains of RLR, N-like loop, and CXCR4 N-terminus 
visualized. For clarity reasons, these residues are not labeled. (c) Side view of the structure in (b). (d) Same as (a) 
but with focus on the negatively charged residues in CXCR4(1–27), i.e. Glu-2, Asp-10, Glu-14, Glu-15, Asp-20, 
Asp-22, Glu-26, and the two positively charged arginine residues in RLR. A potential interaction between Arg-
89 (R89) in RLR and Asp-20 (D20) of the CXCR4 N-terminus is indicated by a yellow dotted line.
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Figure 7. Structure comparison of MIF, CXCL12, and human β-defensin-3. (a) Comparison of the amino acid 
sequences, highlighting residues/motifs that have been implicated in binding to CXCR4. MIF: RLR (magenta, 
bold), Arg-94 (R94; magenta), N-like loop (suggested to contribute to site 1 binding35; blue), Pro-2 (suggested 
to contribute to site 1 binding35; red), extended N-like loop (suggested to contribute to site 1 binding35; 
beige), pseudo-ELR motif (discontinuous, contributes to MIF/CXCR2 interface; green), Met-1 (cleaved upon 
expression; grey). CXCL12: KHLK motif (magenta, bold), Lys-1/Arg-8/Arg-12 charge cluster (magenta), 
RFFESH motif (orange). HBD3: Lys-8/Lys-32/Arg-36 charge cluster (magenta). (b) Comparison of the three-
dimensional structures. Ribbon structures of the respective monomers are shown, with the backbones depicted 
in green. The corresponding color code and the captions for the residues/motifs that have been implicated in 
CXCR4 binding are as in (a); in the MIF structure, the ‘extension’ of the N-like loop (beige color in Fig. 7a) is 
not colored and the processed N-terminal methionine is not shown for clarity reasons. CXCL12 is depicted in 
two views (i) to highlight the KHLK motif and the charge cluster (top right) and (ii) the RFFESH motif (bottom 
right). Protein structures were produced/visualized with PyMOL.
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previously been implicated in MIF/CXCR4 binding and peptide CXCR4(1–27) was found to bind to WT-MIF 
with a Kd of approximately 10 µM35.
A fluorescence titration-based binding experiment in our current study showed that increasing concentra-
tions of CXCR4(1–27) did not evoke conformational changes of a fluorescently labeled MIF mutant in which 
all three residues of the RLR sequence were substituted to alanine. Thus, we conclude that the triple mutant 
R87A-L88A-R89A-MIF does not bind to the CXCR4 N-terminus. This confirms the peptide array obser-
vations and suggests that the RLR sequence also is important for CXCR4(1–27) binding in the context of the 
three-dimensional –folded- MIF structure.
Importantly, the site-specific RLR mutant had a fully ablated CXCR4 signaling response in S. cerevisiae trans-
formants specifically expressing CXCR4 and a reduced CXCR4-dependent lymphocyte migration response when 
compared with RLR-containing WT-MIF. The CXCR4-dependent yeast-signaling assay is a powerful functional 
tool37, as it represents a signaling-competent cell system that does not express any of the other MIF receptors. 
Accordingly, a signaling response can be directly linked to interactions between MIF and CXCR4. The MIF 
R87A-L88A-R89A triple mutant elicited a reduced cell migratory response in CXCR4-expressing JVM-3 lympho-
cytes compared to WT-MIF, but contrary to CXCR4-mediated signaling in the S. cerevisiae system the response 
was not completely abolished. While the mutant failed to show any chemotactic activity at the optimal concentra-
tion of WT-MIF (16 nM), a slight increase in activity was noted at 32 nM, although this effect did not reach sta-
tistical significance. The yeast only signals through a modified G-protein to induce expression of β-galactosidase, 
whereas JVM-3 cells signal through both G-proteins and β-arrestin. β-arrestin is known to have roles in cellular 
Figure 8. Comparison of the surface charges of MIF, CXCL12, and human β-defensin-3. Comparison of the 
three-dimensional structures of MIF, CXCL12, and human β-defensin-3 (HBD3) focusing on the surface 
charges. The relevant positively charged residues, the RLR, and the KHLK sequence, as well as the RFFESH 
motif are indicated as shown. Blue, positively charged residues arginine, lysine, or histidine; red, negatively 
charged residues aspartate and glutamate. Protein structures were produced/visualized with PyMOL.
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chemotaxis69. Another explanation for the subtle differences in WT-MIF versus triple mutant behavior between 
the yeast and JVM-3 chemotaxis cell systems could be that JVM-3 cells also express the MIF receptor CD74 
(unpublished observations). Overall, ablation or reduction of MIF-mediated CXCR4-dependent cell responses 
by R87A-L88A-R89A-MIF in the yeast and JVM-3 lymphocyte assays suggests that the RLR sequence is critically 
involved in the MIF/CXCR4 interface.
The RLR mutant bioactivity data together with our structure-activity studies point toward a role for RLR in 
CXCR4 binding and CXCR4-mediated signaling. In fact, RLR may represent a novel hot segment in the binding 
interface70, but our study also has some limitations. The peptide spot array method is based on interactions of 
surface-immobilized 10–20-mer peptides with their binding partner. These peptides can only represent regions 
that are linear in nature with many different conformations. In our experiments, the RLR-containing peptides 
or their mutant counterparts were probed with biotinylated CXCR4(1–27). There are 7 acidic residues (Asp or 
Glu, including a di-Glu repeat) within the CXCR4 sequence 1–27 that could interact with the RLR motif by elec-
trostatic/polar interactions. A role for electrostatic interactions between CXCR4(1–27) and MIF-RLR is further 
supported by our alanine scanning and the molecular docking results.
Alanine scanning shows that substitution of Glu-86, the acidic glutamic acid residue immediately preced-
ing RLR, by alanine, causes a marked increase in the interaction signal between biotin-CXCR4(1–27) and the 
respective RLR-containing peptide. Although our alanine scanning and molecular docking data did not lend 
fully unanimous support to the notion that positive charges in or around the RLR sequence are the decisive factor 
of the binding force at the MIF/CXCR4-N-terminus interface, the E86A mutation was noticeable in that it led to 
an enormous increase in binding signal between MIF-RLR-containing peptide and biotin-CXCR4(1–27) in two 
independent MIF peptides (peptides 75–89 and 84–98), increasing the net positive charge in this region by +1. 
In the same vein, substitution of Arg-94 by alanine in peptide 84–98 led to a marked reduction in binding signal. 
The molecular docking approach between MIF and the CXCR4-N-terminus and the performed sequence and 
three-dimensional structure comparisons between MIF and CXCL12 as well as HBD3 confirmed the conclusion 
that positive charge interactions critically contribute to the site 1 interface between MIF and CXCR4. Arg-89 of 
MIF may engage in a binding interaction with Asp-20 of CXCR4 and numerous similarities were noted between 
the relevant positive charge clusters in CXCL12 (i.e. the KHLK motif) or HBD3 and the RLR area of MIF with its 
excess of net positive charges.
The alanine mutations of RLR do not interfere with the overall structural integrity of protein. To this end, CD 
spectroscopy of R87A-L88A-R89A-MIF confirmed the overall structural integrity of the folded mutant protein, 
although a 20% decrease in ordered secondary structural content was observed that was paralleled by a corre-
sponding increase in unordered elements. However, CD can only determine average changes across all secondary 
structure elements of a protein and it is unknown whether e.g. the reduction in α-helix content affected the sec-
ond α-helix of MIF, at the far C-terminal end of which RLR is located. Moreover, some of the available structures 
of human MIF place the RLR segment C-terminal of the α-helix36. Thus, RLR might reside in a less structured 
part of the MIF protein. Furthermore, although MIF has been suggested to interact with its receptor CD74 as a 
trimer71, it is currently unknown which oligomeric form binds to CXCR4. Monomeric and dimeric species of 
MIF have been reported42,72,73 and a MIF monomer may have a higher structural flexibility than the more rigid 
trimeric architecture. Our molecular docking experiments were performed with monomeric MIF, yielding rea-
sonable global binding energies regarding the interaction with the N-terminal of CXCR4 and suggesting that the 
MIF RLR site and/or the N-like loop could engage in numerous direct interactions with the N-terminal 27 resi-
dues of CXCR4. The experiments performed in this study cannot fully rule out the possibility that the mutation 
of RLR leads to slight changes in the secondary or tertiary conformation of MIF, but the data obtained strongly 
point toward the conclusion that the three residues play a strong role in the interaction with CXCR4. The future 
X-ray crystallographic elucidation of the three-dimensional structure of R87A-L88A-R89A-MIF and eventually a 
co-crystal structure between WT-MIF and CXCR4(1–27) or full-length CXCR4 will clarify the precise position-
ing of RLR at the MIF/CXCR4 interface.
All five randomized control peptides of MIF(75–90) showed an impaired binding signal to CXCR4(1–27), 
when compared to the wildtype sequence featuring a preserved RLR site. This experiment suggested that, in 
addition to the net positive charge in the RLR region, the RLR sequence itself is critical for CXCR4 binding. 
Comparing the MIF/CXCR4 interaction with those of the other known CXCR4 ligands confirms this notion and 
further supports the role of the positive charge cluster in MIF. CXCL12 is one of the most basic chemokines, with 
an overall charge of +8. The corresponding net charge of the extracellular regions of CXCR4 is −9. Interestingly, 
the post-translational sulfation of tyrosine residues Tyr-7, Tyr-12, and Tyr-21 in the N-terminus of CXCR4, intro-
ducing additional negative charges, has been suggested to further enhance CXCL12 binding74,75, but the influence 
of post-translational CXCR4 modifications on MIF effects have not yet been studied.
With respect to the MIF RLR sequence, there is an HLK sequence (residues 25–27) in CXCL12. The strong 
increase in signal intensity of the ALRL mutant peptide as compared to a MIF ERLR peptide might thus corre-
spond to the CXCL12 KHLK motif. Although in the absence of a MIF-CXCR4, nor CXCL12-CXCR4, structure it 
is difficult to know how MIF is oriented with respect to CXCR4, given that the MIF Glu-86 and CXCL12 Lys-24 
are in the same position of the RLR and HLK residues of both proteins, respectively, gives support that this region 
is important for binding to CXCR4. The available vMIP-II-CXCR4 structure5 only is of limited usefulness in 
this regard. From a structural point of view, the vMIP-II residues at the position of the CXCL12 residues KHLK 
have no charge and are on the β-strand nearest to receptor interactions. However, it is not known what the subtle 
rotations of the proteins CXCL12 and CXCR4 relative to the vMIP-II-CXCR4 structure are. And it is far harder 
to predict what the structure of the MIF–CXCR4 complex is. Similar considerations apply to the charge cluster 
of HBD350.
It needs to be emphasized that the binding sequences and properties of MIF, CXCL12, and HBD3 do not need to be 
exactly the same for binding to occur. This notion is borne out by the sequence of vMIP-II bound to CXCR45 versus the 
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sequence of CXCL1239 as well as the comparison of the vMIP-II-CXCR4 and CXCL12-CXCR4(1–38) co-structures5,49. 
Moreover, GPCRs are known to be very dynamic are able to accommodate different types of structures.
In summary, identification of the RLR tripeptide of the atypical chemokine MIF provides important structural 
information to our understanding of the MIF/CXCR4 binding site and helps to further distinguish this interface 
from that between CXCR4 and its cognate ligand CXCL12. This should also aid in the design drug-targeting 
approaches that are specific to MIF while leaving homeostatic CXCR4/CXCL12 or tissue-protective MIF/CD74 
responses unaffected.
Methods
Cell culture, endotoxin assay, and reagents. JVM-3 cells (ACC-18) are a chronic B cell leukemia cell 
line and were kindly provided by Prof. M. Hallek, University of Cologne Medical School, Cologne, Germany. 
JVM-3 were grown in RPMI media with 1% penicillin/streptomycin and 10% fetal bovine serum (Invitrogen-
Thermo Fisher Scientific, Karlsruhe, Germany) essentially as described previously48. Miscellaneous cell culture 
reagents also were bought from Invitrogen-Thermo Fisher Scientific and from PAA (Pasching, Austria). LPS 
content of the purified WT-MIF and RLR mutant proteins was tested by limulus amoebocyte assay (LAL, Lonza, 
Cologne, Germany) following the manufacturer’s recommendation. All other reagents were obtained from Sigma, 
Merck, Roth, or Calbiochem, and were of the highest purity degree available.
Peptide synthesis. All peptides were produced by Fmoc solid phase synthesis (SPPS) and purified by 
high-performance liquid chromatography (HPLC) essentially as described previously76. The quality was checked 
by mass spectrometry analysis. Biotinylated N-terminal peptide human CXCR4(1–27) was synthesized by 
Fmoc-SPPS and biotin introduced N-terminally following an amino-caproic acid (Aca) spacer. RLR-containing 
MIF peptides 76–90 (YSKLLCGLLAERLRI) and 86–100 (ERLRISPDRVYINYY) were custom-synthesized by 
Peptide Specialty Laboratories (PSL, Heidelberg, Germany).
Recombinant proteins, cloning of R87A-L88A-R89A-MIF, and SDS-PAGE/Western blotting. 
SDF-1α/CXCL12 was purified as previously described77. Biologically active recombinant human MIF (rMIF) was 
expressed and purified essentially as described40.
The RLR triple alanine mutant of MIF (MIF(R87A-L88A-R89A-MIF)) was cloned into the pET11b vector by 
site-specific mutagenesis using Quikchange II (Agilent, Waldbronn, Germany) and the cDNA of wildtype (WT) 
human MIF as template40 and expressed in E. coli BL21/DE3. Mutagenic primers were first synthesized to create 
single mutations within the the wild-type human MIF insert40. Subsequent mutagenic reactions created double 
mutant and triple mutant plasmids. Plasmids were sequenced to verify the accuracy and location of the mutations 
within the vector.
The RLR mutant protein was expressed in E. coli B21/DE3 (Merck-Novagen, Darmstadt, Germany). Cultures 
of 250 mL were grown at 37 °C until an optical density of 0.6–0.8 was reached. A final concentration of 1 mM 
isopropyl 1-thio-ß-D-galactopyranoide (IPTG) was used to induce protein expression for an additional 3.5 h. 
Bacteria were then harvested in aliquots of 50 mL by centrifugation, and the cell pellets were frozen at −20 °C for 
later use. For protein purification, cells pellets were resuspended in 2 mL Tris-based saline (25 mM Tris, 10 mM 
NaCl, pH 7.5). The bacteria were lysed under 75 mPa using a French Press (Emulsi-Flex C5, Avestin, Germany). 
Cell debris was removed by centrifugation at 38000 g for 30 min. To further reduce debris, the supernatant, 
referred to as the raw protein extract of the bacterial lysate, was sterile-filtered through a 0.22 μm membrane 
filter. Recombinant RLR mutant protein was first purified using anion exchange chromatography (Q sepharose, 
GE Healthcare, Freiburg, Germany) using a fast protein liquid chromatography system (FPLC, ÄKTA Pure, GE 
Healthcare). The system was equilibrated with Tris-buffered saline, pH 7.5. The triple mutant protein was eluted 
using a buffer gradient (ending in 25 mM Tris, 1 M NaCl, pH 7.5). Mutant protein-containing fractions were 
pooled and stored on ice. Following Q sepharose, the protein was further purified by size exclusion chroma-
tography (SEC, Superdex 75, GE Healthcare) in 20 mM sodium phosphate buffer, pH 7.2, i.e. buffer conditions 
compatible with MIF bioactivity. R87A-L88A-R89A-MIF was sterile-filtered and stored at 4 °C until further use. 
The RLR mutant protein was obtained free of endotoxin contamination (<20 pg LPS/µg protein), suitable for 
subsequent biochemical and cell-based tests. Fractions containing the RLR mutant protein were confirmed by 
SDS-PAGE and Western blotting.
SDS-PAGE was performed in 15% gels under reducing conditions. Gels were either silver-stained or processed 
for Western blotting. For silver staining, gels were fixed for 16 h in 50% methanol/10% acetic acid in addition to 
10% fixation enhancer (161–0461, BioRad, Munich, Germany). For Western blotting, proteins were transferred 
to nitrocellulose membranes at 20 V for 90 min. Blots were blocked with 5% bovine serum albumin and stained 
for MIF or RLR mutant bands using our rabbit polyclonal anti-MIF antibody (Ka345)23. Both gels and blots were 
imaged with the LiCor Odyssey Fc system (LICOR Biotechnology GmbH, Bad Homburg, Germany).
CXCR4-specific yeast-signaling assay. The S. cerevisiae strain (CY12946) expressing a functional CXCR4 
has been previously described37. Upon CXCR4 activation, MAP kinase signaling transcribes and translates 
β-galactosidase (lacZ), which is quantified by an enzymatic assay. To study the CXCR4 signaling by extracel-
lular WT-MIF or R87A-L88A-R89A-MIF, CY12946 strain was transformed with CXCR4 in Cp4181 and β-gal 
in Cp1584. The transformed cells were grown overnight in selective medium. The cells were diluted to 0.3–0.8 
OD600 nm and incubated with WT-MIF or R87A-L88A-R89A-MIF. WT-MIF was tested at a final concentration 
of 10 and 20 μM, showing dose-dependent activation of CXCR4 signaling. Due to solubility restrictions of the 
corresponding stock solution, the triple alanine mutant could only be tested at a concentration of 10 µM. The 
activation of CXCR4 was quantitated by β-galactosidase activity using Beta glo kit (Promega). The data shown is 
the mean ± SD of 3–9 replicates representing three-to-four experiments.
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Peptide array methodology. The peptide microarray method using glass slide technology has been 
described previously35. Briefly, following stepwise SPOT synthesis (Intavis MultiPep RSi/CelluSpot Array, 
Cologne, Germany, or JPT, Berlin, Germany), the peptides were dispensed on an activated glass surface using a 
droplet-depositing system. Target peptides were immobilized chemo-selectively and purified by reaction of the 
peptides with the modified glass surface resulting in the formation of a covalent bond, which allowed the removal 
of all truncated and acetylated sequences by subsequent washing steps. After all peptides were arrayed on the glass 
surface, active residues were passivated. Analysis of interactions was performed using a microarray processing 
station (Intavis Slide Spotting Robot). The microarrays were incubated with biotinylated CXCR4(1–27) peptide. 
For determination of false-positives, one microarray was incubated with fluorescently-labeled streptavidin only. 
After incubation with 200 µl of biotinylated CXCR4(1–27) (10 µg/ml) in blocking buffer for 30 min and washing 
with Tris-buffered saline (TBS) buffer containing 0.1% Tween 20, the array was developed with Cy5-streptavidin 
or horse-radish peroxidase (HRP)-streptavidin in blocking buffer. Scanning or chemiluminescence imaging at 
the appropriate wavelength showed the signal intensity as a single measurement for each peptide and the intensity 
of each fluorescent spot on the scanned or imaged microarray slide was quantified. Each spot-feature was ana-
lyzed for total intensity and background intensity and corrected for background. Data shown represent the mean 
values of corrected mean/median of signal intensities from two or three identical subarrays on each microarray 
image.
Lymphocyte chemotaxis assay. Migration assays using the CXCR4-expressing JVM-3 B cell line were 
performed in a transmigration well as previously described32 using the following modifications. Briefly, JVM-3 
B cells were sub-cultured and transferred to media without FBS. A migration assay was performed using 24-well 
format Transwell membranes (Sigma-Corning; 5 µm pore size) containing 1 × 106 JVM-3 cells in the upper cham-
ber. 8 nM or 16 nM of WT-MIF and 8 nM, 16 nM, or 32 nM of R87A-L88A-R89A-MIF was added to the lower 
chamber as chemoattractant. As positive control, 8 nM CXCL12 was used. Wells without chemoattractant served 
as negative control and were used to normalize migration effects to ‘chemotactic index’ (number of migrated 
cells in the presence of chemoattractant divided by the number of migrated cells in the absence of the chemoat-
tractant) – as described previously30. In the inhibition assay, 10 nM, 100 nM, or 1 µM of the RLR-containing MIF 
peptides 76–90 (YSKLLCGLLAERLRI) or 86–100 (ERLRISPDRVYINYY) were pre-incubated with WT-MIF 
for 30 min prior to the migration process and also added to the upper chamber. Cells were allowed to migrate 
for 24 h. After migration, cells in the lower chamber were counted using Countbright absolute counting beads 
(Invitrogen) using a FACSVerse flow cytometer (BD Biosciences, Heidelberg, Germany).
Circular dichroism spectroscopy. Far-UV circular dichroism (CD) spectra were recorded in a Jasco 700 
CD spectropolarimeter (Jasco Labor- u. Datentechnik GmbH, Groß-Umstadt, Germany). Scans were recorded 
at 25 °C between 195 and 250 nm as an average of three scans and smoothed to obtain the final data. Spectra were 
collected at 1.0 nm intervals with a bandwidth of 1 nm in a buffer containing 10 mM sodium phosphate, pH 7.2. 
Spectra of WT-MIF and R87A-L88A-R89A-MIF were measured at concentrations of 1, 2.5, and 5 µM and were 
recorded in a 1 cm quartz cuvette. CD spectra are presented as a plot of mean residue ellipticities. Dynode voltage 
values generally were below 800 and did not interfere with CD measurements. Secondary structure fractions 
were quantitated by the Dichroweb online software webtool by deconvolutions of CD spectra using ContinLL at 
DichroWeb and the reference spectra set 743,44.
Fluorescence spectroscopy. Fluorescence spectroscopy titrations of R87A-L88A-R89A-MIF with the 
N-terminal peptide of CXCR4 were performed as previously described for WT-MIF35. Briefly, titrations were 
recorded in quartz cuvettes in a JASCO FP-6500 fluorescence spectrophotometer. MIF-CXCR4 interactions were 
probed by titrating CXCR4 peptide(1–27) against Alexa Fluor-488- R87A-L88A-R89A-MIF. The triple mutant 
MIF was applied at a concentration of 6.5 nM in 20 mM sodium phosphate buffer, pH 7.2, and the peptide was 
added at ratios of 1:0.76, 1:1.52, 1:7.63, 1:76.3, and 1:763 in the same buffer. Changes in Alexa Fluor-488 emission 
were recorded between 500 and 600 nm wavelength.
Structural models. Three-dimensional structures of human MIF, human CXCL12, and human β-defensin-3 
(HBD3) were visualized using the PyMOL Molecular Graphics System, version 1.8.2.2 (Schrödinger, LLC, New 
York). Surface charge distributions were calculated using PyMOL’s protein contact potential function. The struc-
tures were modeled according to the Protein Data Bank (PDB) file for human MIF (PDB identifier: 3DJH), 
human CXCL12 (PDB identifier: 1SDF), HBD3 (3KJ6), human CXCR4 (Chain B of 2N55), or our molecular 
docking results. In the structure file of the N-terminus of CXCR4, there are two additional amino acids – glycine 
and serine – prior to the coding sequence. For clarity in the visualization, these residues were removed before 
producing the images.
Molecular docking. For molecular docking simulations of MIF with the N-terminus of CXCR4, we used the 
PatchDock + FireDock framework. The online tool PatchDock (Beta 1.3 version) for rigid body docking was used 
with complex type set to default and a clustering root-mean-square deviation (RMSD) of 4.0 Å78. Monomeric 
MIF (chain A of the human MIF structure file 3DJH) was used as a ‘ligand’, the N-terminal region (residues 1–38) 
of CXCR4 (chain B of the structure file 2N55) as the ‘receptor’. The 1000 best solutions obtained by PatchDock 
were then submitted to FireDock for refinement by introducing flexibility in the docking process, and rescoring 
according to free energy calculations79,80. Out of the calculated complexes, the highest-ranking solution was cho-
sen for further analysis and visualization.
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Statistical analysis. Data are expressed as means ± SD. Student’s t-tests (two-sided, unpaired) was per-
formed to compare experimental groups. Differences with a value of p < 0.05 were considered statistically 
significant.
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